INDIA – India IVF, founded by Dr. Richika Sahay and Dr. Somendra Shukla in 2014, has secured US $1.25 million in pre-Series A funding from Tomorrow Capital.
This investment marks India IVF’s first external funding, following a decade of profitable operations and expansion into five North Indian centers, including Delhi NCR and Srinagar.
This milestone funding will support India IVF’s plans to expand its reach across North India, aiming to make advanced fertility care more accessible in underserved communities.
India IVF, which has operated profitably for a decade across five North Indian clinics, including in Delhi NCR and Srinagar, delivers comprehensive support for individuals and couples seeking fertility care.
This goes beyond traditional IVF services to include counseling, emotional support, dietary guidance, yoga, and financial assistance, making it a unique 360-degree fertility platform.
“India IVF has shown remarkable growth and a deep understanding of the unique fertility challenges faced by many Indian couples,” said Rahul Saha, Senior Principal at Tomorrow Capital. “With a tech-enabled, patient-focused approach, they deliver high-quality, personalized care.”
Tomorrow Capital’s investment follows its recent support of VitusCare and IndiShreshtha, further reinforcing its commitment to specialized healthcare ventures.
Co-founder and CEO Dr. Somendra Shukla emphasized that the new partnership with Tomorrow Capital will allow India IVF to widen its impact.
“This partnership will empower us to expand our network and bring advanced fertility solutions to more communities. We look forward to making a positive impact on more families and growing India IVF into a trusted national brand,” he shared.
Making quality fertility care affordable and accessible
India IVF is addressing a large, underserved demographic. According to Dr. Richika Sahay, Co-Founder and Medical Director, accessibility is a core goal of India IVF’s mission.
“Approximately 30 million couples in India suffer from infertility, yet only 10% receive proper treatment due to limited access to fertility care. Our mission is to leverage technology and innovation to deliver quality, affordable, and empathetic fertility care to everyone,” said Dr. Richika.
“With Tomorrow Capital’s support, we’re well-positioned to expand our network and provide affordable, empathetic fertility care to more families,” added Dr. Richika.
India’s IVF services have experienced significant growth, driven by factors like delayed marriages, increasing infertility rates, rising disposable incomes, and growing awareness of fertility treatments.
With success rates of 60-70%, the IVF market has expanded by 20% over the past five years, and experts see further potential for growth.
In particular, in India, a single IVF cycle costs between US $1,200 and US $2,500, substantially lower than in the US, where prices range from US $12,000 to US $14,000, and the UK, where a cycle can cost over US $6,000.
As a result, this affordability makes India a top destination for IVF-related medical tourism, drawing patients both domestically and internationally.
Furthermore, this significant cost advantage, coupled with skilled practitioners and a growing healthcare infrastructure, positions India as an attractive destination for IVF medical tourism.
In line with this trend, the country’s medical tourism industry is set to benefit. Key players in the market, such as Nova IVF (backed by TPG), have already made strategic investments.
For example, Nova IVF acquired a 51 percent stake in Southend Fertility, a Delhi-based IVF chain.
As a result, with an expanding market and cost-effective care, India IVF’s growth marks a significant step toward making quality fertility solutions available to more people across the country.
